Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Document › Details

Sirion Biotech GmbH. (4/7/20). "Press Release: Beam Therapeutics Licenses Sirion Biotech’s LentiBOOST Technology for Its CAR-T pipeline". Martinsried.

Organisation Organisation Sirion Biotech GmbH
  Group PerkinElmer (Group)
Products Product LentiBoost™ technology (lentiviral transduction enhancer)
  Product 2 CAR-T therapy product
Persons Person Thirion, Christian (Sirion Biotech 201106 Managing Director + Founder)
  Person 2 Ott, Sabine (Sirion Biotech 201604– VP Licensing + BusDev before GeneWake + MWG Biotech)

SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products.

CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing technology.

Under the terms of this agreement, SIRION agreed to provide Beam with non-exclusive access to its proprietary lentiviral transduction enhancer LentiBOOST™ for clinical development and commercialization of Beam’s portfolio of CAR-T programs. SIRION will be entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

Dr. Christian Thirion, CEO and founder of SIRION Biotech GmbH explains: “LentiBOOST™ was engineered to improve lentiviral transduction of difficult cell types like T-cells and hematopoietic stem cells. This technology enables robust upscaling of the T-cell production process, and helps to reduce manufacturing costs by lowering the amount of lentiviral vectors needed for production of the cell product while at the same time improving clinical efficacy by increasing vector copy numbers (VCN) per cell. We are delighted that the LentiBOOST™ technology may help Beam further enhance the clinical success of its CAR-T pipeline.”

“LentiBOOST™ is used in an increasing number of clinical trials in the US and in Europe and the technology is more and more considered as a gold standard in manufacturing of cell products. Our non-exclusive licensing strategy makes our technology available to a wide range of companies and research hospitals to boost the efficiency of their various clinical programs,” says SVP of Business Development & Licensing, Dr. Sabine Ott.

About SIRION Biotech GmbH

SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST™ has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.


Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14

Media Contact USA
Lisa DeScenza
Vice President, Integrated Communications
(978) 395-5970

Business Development & Licensing Contact
Sabine Ott, Ph.D., SVP Business Development & Licensing
SIRION Biotech
+49 89-700-96199-19

Record changed: 2020-04-22


Picture [iito] Plain Stupid Simple 650x80px

More documents for PerkinElmer (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px

» top